Ionis Pharmaceuticals, Inc. (IONS) Stock Price & How to Invest

Last updated November 2026

Short answer

IONS is Ionis Pharmaceuticals, the pioneer of antisense (RNA-targeted) drug technology now transitioning into a commercial-stage biotech with its own marketed medicines. Investing here is a bet that its wholly owned launches (Tryngolza, Dawnzera) plus a late-stage pipeline can carry it to sustained profitability. As of November 20, 2026 the shares closed near $27.52, down about 66% in 2026 and 36% over the past month, for a market value of roughly $4.6 billion, after Phase 3 disappointments for eplontersen in cardiomyopathy and pelacarsen in Lp(a) and a slower-than-expected start for Tryngolza in severe hypertriglyceridemia, even as Tryngolza won EU approval for that use in November.

IONS stock price

As of 2026-11-20, Ionis Pharmaceuticals, Inc. (IONS) last closed at $26.58, down 65.1% over the past year. Over the past 52 weeks it has traded between $26.58 and $86.50.

IONS last close
$26.58
1 day
-2.35%
1 month
-39.96%
1 year
-65.07%
52-week range
$26.58 to $86.50
Last close
2026-11-20

Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or Ionis Pharmaceuticals, Inc.'s investor relations page. Walnut is informational, not investment advice.

IONS key stats

At $26.58 on November 20, 2026, Ionis Pharmaceuticals, Inc. (IONS) has a market cap of $4.4B.

Market cap
$4.4B
Price to book
11.2
Beta
0.40

Market cap, P/E and yield are measured at the $26.58 price on November 20, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.

What's new with Ionis Pharmaceuticals, Inc. (IONS)?

The last two weeks for Ionis Pharmaceuticals, Inc., as of November 22, 2026: the price move, the next earnings date, what the company filed with the SEC, and what analysts changed.

  • IONS closed at $26.58 on November 20, 2026, down 8.5% over the past five trading days (from $29.06).
  • On November 9, 2026, Ionis Pharmaceuticals, Inc. filed its quarterly report (10-Q) with the SEC. Read the 10-Q on sec.gov
  • On November 9, 2026, Ionis Pharmaceuticals, Inc. filed an 8-K with the SEC reporting quarterly results (Item 2.02). Read the 8-K on sec.gov
  • On November 18, 2026, Guggenheim lowered its target to $65.00 from $80.00 (Buy).
  • On November 10, 2026, Goldman Sachs lowered its target to $41.00 from $58.00 (Neutral).
  • On November 10, 2026, Morgan Stanley lowered its target to $75.00 from $104.00 (Overweight).

Prices are daily closes from Yahoo Finance. Filings are read from SEC EDGAR every six hours. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.

Ionis Pharmaceuticals, Inc. (IONS) latest quarter

Ionis Pharmaceuticals reported revenue of $243 million for Q3 2026, up 55% from a year earlier (Ionis Pharmaceuticals, Nov 9, 2026).

Revenue
$243 million
up 55% from a year earlier
Diluted EPS
-$0.66
n/a
Total commercial revenue
$136 million
up 17% from a year earlier

Source: Ionis Pharmaceuticals Q3 2026 results, Nov 9, 2026. Full earnings breakdown

What does Ionis Pharmaceuticals, Inc. (IONS) do?

Ionis Pharmaceuticals is a California-based biotechnology company that invented and commercialized antisense technology, a way to design short strands of nucleic acid that silence or modify the RNA behind disease-causing proteins. For decades it operated largely as an R&D and royalty engine, partnering drugs like Spinraza (spinal muscular atrophy, with Biogen) and Wainua (hereditary ATTR polyneuropathy, with AstraZeneca) to larger companies. It now has seven approved medicines covering eight indications and, starting in 2025, launched its first fully owned products, Tryngolza (olezarsen) for familial chylomicronemia syndrome and Dawnzera for hereditary angioedema.

The investment picture is a biotech transition story that has hit turbulence. Quarterly revenue rose from ~$157 million in Q3 2025 to ~$246 million in Q1 2026, ~$268 million in Q2 and ~$243 million in Q3 2026, with trailing-twelve-month revenue of ~$960 million, and losses per share in each 2026 quarter came in well below what analysts expected (Q3: -$0.40 vs -$0.93). The biggest event of the year came in June 2026, when the FDA approved Tryngolza for severe hypertriglyceridemia (sHTG), and on November 17, 2026 the European Commission approved it for the same use, with Sobi holding rights outside the US. The early sHTG launch has been slower than expected: at a mid-November investor conference CEO Brett Monia said more than 1,500 providers had prescribed the drug but 75% had written only one prescription, while reaffirming a peak US sales goal above $3 billion. The pipeline also took hits. Artisan Partners' third-quarter letter cited disappointing Phase 3 results for eplontersen in cardiomyopathy and a second Phase 3 disappointment for pelacarsen in Lp(a), and the fund exited the stock. There were positive data points too: in November Ionis presented two-year data showing increasing clinical benefit for diranersen in early Alzheimer's disease and long-term durability data for Dawnzera. The shares closed near $27.52 on November 20, 2026, down ~66% year to date, ~57% over three months and ~62% over a year, near the bottom of a 52-week range of $26.55 to $86.74. The trailing-twelve-month net loss was ~$547 million. The picture now rewards only investors comfortable with a pipeline-rich biotech that has not yet proven durable profitability and whose largest launch is behind its early expectations.

What's driving Ionis Pharmaceuticals, Inc. (IONS)?

1. Owned commercial launches

Ionis is shifting from a royalty-and-partnership model to selling its own drugs, led by Tryngolza and Dawnzera launched in 2025. Owning full economics on these products, without splitting them with partners, is the core lever for higher revenue and eventual profitability. ZANVASTRO was also launched recently, with management projecting peak US sales above $100 million.

2. Olezarsen in severe hypertriglyceridemia

Olezarsen (Tryngolza) won FDA approval in June 2026 for severe hypertriglyceridemia, as an adjunct to diet to reduce triglycerides and the risk of acute pancreatitis in adults with triglycerides of at least 500 mg/dL, a far larger population than its initial rare-disease indication. In the CORE and CORE2 Phase 3 trials it cut fasting triglycerides by up to 72% versus placebo and, in a pooled analysis, reduced acute pancreatitis events by 85% over 12 months. The European Commission approved it for sHTG on November 17, 2026, and Sobi estimates over $1 billion in peak European sales. Uptake has been slower than expected, with most prescribers writing a single prescription so far, though management says payers are covering the drug to its label, Ionis lowered the price when the indication broadened, and repeat prescribing is rising. Management still guides peak annual US net sales above $3 billion, an estimate that assumes Arrowhead's competing REDEMPLO enters the market (Arrowhead expects approval in sHTG in Q2 2027). A once- or twice-yearly follow-on, ION775, is in Phase 2.

3. Late-stage pipeline after two setbacks

Ionis has four Phase 3 programs and a broad antisense platform across rare, neurological and cardiometabolic diseases. 2026 brought disappointing Phase 3 results for eplontersen in cardiomyopathy and for pelacarsen in Lp(a), two programs that had carried large expectations. Upcoming catalysts include Phase 3 data for obudanersen in Angelman syndrome in the second half of 2027, and diranersen showed increasing clinical benefit at two years in early Alzheimer's disease in data released November 17, 2026.

4. Balance sheet

The company ended 2025 with roughly $2.7 billion in cash and investments and held about $1.9 billion at September 30, 2026, against about $2.2 billion of debt, much of it convertible notes. That cash gives it runway to fund launches and trials without immediate financing pressure, though trailing operating cash burn of roughly $544 million a year means the cushion is not unlimited and the debt will eventually need to be repaid or refinanced.

What are the risks to Ionis Pharmaceuticals, Inc. (IONS)?

Ionis still operates at a loss, with a trailing-twelve-month net loss of about $547 million and operating cash outflow of about $544 million, so profitability remains unproven. The share price has fallen about 66% in 2026 and 36% in the month to November 20, 2026, showing how sharply sentiment can turn on clinical and launch news. Two Phase 3 programs, eplontersen in cardiomyopathy and pelacarsen in Lp(a), disappointed in 2026, which removes part of the pipeline value investors had assigned. The Tryngolza sHTG launch is off to a slower start than expected, and the company's $3 billion-plus peak sales goal depends on repeat prescribing broadening; Arrowhead expects a competing drug, REDEMPLO, to be approved in sHTG in Q2 2027. The Tryngolza sHTG label carries warnings for hypersensitivity reactions and liver enzyme abnormalities, which could shape uptake. It competes directly with Alnylam's RNA-interference platform in overlapping rare and cardiovascular diseases, and some of its biggest products are shared with partners like Biogen and AstraZeneca who control much of the commercial reach. Debt of about $2.2 billion now exceeds cash of about $1.9 billion. Pricing pressure, safety findings, and patent or competitive erosion on older drugs add further uncertainty. As a biotech, the shares can be highly volatile around clinical and regulatory events.

What is the Ionis Pharmaceuticals, Inc. (IONS) forecast?

23 analysts publish price targets on IONS, averaging $67.83 as of November 2026, or +155.2% against the $26.58 share price on November 20, 2026. The published targets run from $41.00 to $105.00, a wide spread, and the ratings split 21 buy, 4 hold, 0 sell. Over the last six months there have been 2 raises and 9 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full IONS forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

Is IONS a buy or a sell?

We give no verdict on Ionis Pharmaceuticals, Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Owned commercial launches. Ionis is shifting from a royalty-and-partnership model to selling its own drugs, led by Tryngolza and Dawnzera launched in 2025. The most optimistic published target, $105.00, assumes this works close to its best case.

The case against. Ionis still operates at a loss, with a trailing-twelve-month net loss of about $547 million and operating cash outflow of about $544 million, so profitability remains unproven. The most pessimistic target, $41.00, is roughly what IONS is worth if this bites instead.

Read the full bull and bear case on IONS, including what would have to change to break either one. Walnut is not an investment adviser.

Has Ionis Pharmaceuticals, Inc. (IONS) split its stock?

No. Ionis Pharmaceuticals, Inc. (IONS) has not split its stock in the last 10 years. The statement covers only the window we check, so an older split in the company’s history is possible. It also matters less than it once did: fractional shares mean a high price per share no longer keeps smaller investors out, which removed most of the practical reason to split.

How is Ionis Pharmaceuticals, Inc. (IONS) valued?

Market cap, P/E and dividend yield at today's price are in the IONS key stats above. The business figures below come from Ionis Pharmaceuticals, Inc.'s reported results as of November 2026 and change when it next reports.

  • Revenue (TTM): ~$960M (+~55% YoY latest quarter); 2025 revenue ~$944M
  • Q3 2026 revenue: ~$243M (Q2 2026 ~$268M); EPS -$0.40 vs -$0.93 estimate
  • Revenue consensus: ~$923M for 2026; ~$1.15B for 2027
  • Net income (TTM): ~-$547M (EPS ~-$3.35)
  • Cash and debt: ~$1.9B cash and investments; ~$2.2B debt (Sept 30, 2026)

As of November 2026: Ionis trades as a growth-stage biotech, valued on future product sales and not current earnings since it remains unprofitable. After a ~66% fall in 2026 the stock sits near 4.8 times trailing sales, down from about 8 times in mid-October, as two Phase 3 setbacks and a slow early sHTG launch reset expectations even though quarterly losses keep coming in narrower than forecast. The 23 analysts tracked have a mean target near $67.83, well above the price, and the market value of ~$4.6 billion is now not far above the company's ~$1.9 billion of cash.

Who competes with Ionis Pharmaceuticals, Inc. (IONS)?

RNA-targeted medicine peers

Alnylam Pharmaceuticals is the closest competitor, using RNA interference (a different mechanism from Ionis's antisense) to target overlapping rare and cardiovascular diseases, and it carries a substantially larger market cap. Arrowhead Pharmaceuticals competes head-on in severe hypertriglyceridemia with REDEMPLO, which it expects to be approved for that use in Q2 2027. These companies lead the broader oligonucleotide-therapeutics field alongside players like Astellas.

Large pharma in shared indications

In big categories such as cardiometabolic and amyloid disease, Ionis faces established pharmaceutical companies with far larger sales forces, including some that are simultaneously partners (AstraZeneca on Wainua, Biogen on Spinraza and Qalsody) and potential competitors in adjacent treatments.

Rare-disease and cardiometabolic specialists

Individual products compete with focused biotech and specialty-pharma rivals in areas like hereditary angioedema, hypertriglyceridemia, and neuromuscular disease, where alternative therapies and newer entrants can pressure market share and pricing.

What stocks are similar to Ionis Pharmaceuticals, Inc. (IONS)?

Other names that sit close to IONS: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. They are useful if you want to spread one thesis across several tickers.

How to invest in Ionis Pharmaceuticals, Inc. (IONS)

There are three common ways to get IONS exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so IONS sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where IONS fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

The bottom line on Ionis Pharmaceuticals, Inc. (IONS)

Ionis is an antisense-drug pioneer turning a long-running research engine into commercial products, so the story hinges on launch execution and pipeline readouts more than current profits. The June 2026 US approval and November 2026 EU approval of Tryngolza in severe hypertriglyceridemia opened its largest market yet, but the launch has started slowly, two partnered Phase 3 programs disappointed, and a ~66% share-price fall in 2026 shows how much skepticism the stock now carries.

More on Ionis Pharmaceuticals, Inc. (IONS)

Whether IONS is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is IONS a buy or a sell?, and where the stock could go from here in the IONS stock forecast.

For income investors, whether IONS pays a dividend and how the payout looks is covered in does IONS pay a dividend? And to weigh IONS against a peer, read the full side-by-side comparisons: IONS vs ALNY and IONS vs ARWR.

Wondering how IONS fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about Ionis Pharmaceuticals, Inc.

Ask Walnut's AI anything about IONS and see how it fits what you own.

FAQ

What does Ionis Pharmaceuticals do?

+

Ionis is a commercial-stage biotechnology company that pioneered antisense technology, designing RNA-targeted drugs that silence or modify disease-causing proteins. It has seven approved medicines covering eight indications and develops a broad pipeline across rare, neurological, and cardiometabolic diseases.

Is Ionis profitable?

+

Not yet. Revenue is growing, but the company is investing heavily in launches and trials. Over the twelve months to September 2026 it lost about $547 million on ~$960 million of revenue, and analysts expect losses to continue in 2027 (consensus EPS about -$2.03). Profitability depends on its owned products, especially Tryngolza, scaling up.

What are Ionis's most important drugs?

+

Its first wholly owned launches are Tryngolza (olezarsen) for familial chylomicronemia syndrome and now severe hypertriglyceridemia, and Dawnzera for hereditary angioedema. It also has partnered products including Spinraza, Wainua, Qalsody, Tegsedi, and Waylivra, and recently launched ZANVASTRO.

Why is olezarsen important to Ionis?

+

Olezarsen (Tryngolza) was approved by the FDA in June 2026 and by the European Commission on November 17, 2026 for severe hypertriglyceridemia, after Phase 3 trials showed triglyceride cuts of up to 72% and 85% fewer acute pancreatitis events. Management guides peak annual US net sales above $3 billion and partner Sobi sees over $1 billion in Europe, although the early US launch has been slower than expected, with 75% of its 1,500-plus prescribers having written one prescription by mid-November.

How is antisense different from RNA interference?

+

Both target RNA directly instead of proteins, but they use different molecular mechanisms. Ionis is the leader in antisense oligonucleotides, while its main peer Alnylam specializes in RNA interference. The two approaches sometimes address overlapping diseases.

Who are Ionis's main competitors?

+

Alnylam Pharmaceuticals is the closest comparable in RNA-targeted medicine, and Arrowhead Pharmaceuticals is the most direct rival in severe hypertriglyceridemia. Ionis also competes with large pharmaceutical companies in shared indications and with specialty biotech firms in specific rare and cardiometabolic diseases.

How financially stable is Ionis?

+

The company ended 2025 with about $2.7 billion in cash and investments and held roughly $1.9 billion at September 30, 2026, against about $2.2 billion of debt. That gives it runway to fund launches and clinical programs, though it is still spending more than it earns, with about $544 million of operating cash outflow over the trailing year.

What makes Ionis stock volatile?

+

As a biotech, its value is tied to regulatory decisions, launch trajectories, and clinical readouts. In 2026 two Phase 3 disappointments and a slow early sHTG launch drove the shares from a 52-week high of about $87 to about $27.52 on November 20, 2026, down about 66% year to date, which shows how individual events can move the stock sharply.

How did Ionis do in its latest quarter?

+

In the third quarter of 2026, Ionis reported revenue of about $243 million, down from about $268 million in the second quarter, and a loss of $0.40 per share, much narrower than the ~$0.93 analysts expected. The net loss was about $110 million. Consensus for the fourth quarter is about $181 million of revenue and a $0.93 loss per share.

How has IONS stock performed in 2026?

+

As of November 20, 2026, IONS closed near $27.52, down about 66% year to date, about 36% over one month, about 57% over three months and about 62% over one year, just above the bottom of its 52-week range of roughly $26.55 to $86.74. UBS had upgraded the shares to Buy with an $88 target on October 15, 2026. Past performance does not predict future returns. Walnut is not an investment adviser.

What Phase 3 setbacks did Ionis have in 2026?

+

Artisan Partners' third-quarter 2026 letter described disappointing Phase 3 results for eplontersen in cardiomyopathy and a second Phase 3 disappointment for pelacarsen in Lp(a), after which the fund sold its position. Eplontersen is already approved as Wainua for hereditary ATTR polyneuropathy, so the cardiomyopathy result limits an expansion, not the existing product. Both programs had been seen as large future markets.

Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with Ionis Pharmaceuticals, Inc.'s investor relations page or your broker before making investment decisions.